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Introduction
Tissue scarring, characterized by cell activation, excessive de-
position of ECM, and extravascular fi brin deposition, is con-
sidered a limiting factor for tissue repair. Fibrin, the major 
substrate of the serine protease plasmin, is a provisional ma-
trix deposited after vascular injury (Bugge et al., 1996). The 
two plasminogen activators (PAs), namely tissue plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA) 
and their inhibitors, such as plasminogen activator inhibitor-1 
(PAI-1), are key modulators of scar resolution by spatially and 
temporally regulating the conversion of plasminogen to plasmin 
resulting in fi brin degradation and ECM remodeling (Lijnen, 
2001). In the peripheral nervous system, previous work by us 
and others showed that inhibition of fi brinolysis in mice 
 defi cient in plasminogen or tPA exacerbated axonal damage 
(Akassoglou et al., 2000) and impaired functional recovery 
 after nerve injury (Siconolfi  and Seeds, 2001). In accordance, 
mice defi cient for fi brinogen showed increased regenerative 
capacity (Akassoglou et al., 2002). Studies of fi brin deposition 
in human diseases, in combination with experiments from 
mice defi cient in plasminogen and PAs, have provided infor-
mation about a wide range of physiological and pathological 
conditions that are exacerbated by defective fi brin degrada-
tion, such as wound healing, metastasis, atherosclerosis, lung 
ischemia, rheumatoid arthritis, muscle regeneration, and mul-
tiple sclerosis (MS) (Degen et al., 2001; Adams et al., 2004). 
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Clearance of fi brin through proteolytic degrada-tion is a critical step of matrix remodeling that contributes to tissue repair in a variety of patho-
logical conditions, such as stroke, atherosclerosis, and 
pulmonary disease. However, the molecular mechanisms 
that regulate fi brin deposition are not known. Here, we 
report that the p75 neurotrophin receptor (p75NTR), a TNF 
receptor superfamily member up-regulated after tissue 
injury, blocks fi brinolysis by down-regulating the serine 
protease, tissue plasminogen activator (tPA), and up-
regulating plasminogen activator inhibitor-1 (PAI-1). 
We have discovered a new mechanism in which phospho-
diesterase PDE4A4/5 interacts with p75NTR to enhance 
cAMP degradation. The p75NTR-dependent down-regulation 
of cAMP results in a decrease in extracellular proteolytic 
activity. This mechanism is supported in vivo in p75NTR-
defi cient mice, which show increased proteolysis after 
sciatic nerve injury and lung fi brosis. Our results reveal a 
novel pathogenic mechanism by which p75NTR regulates 
degradation of cAMP and perpetuates scar formation 
 after injury.
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However, the molecular mechanisms that regulate proteolytic 
activity remain unclear.
In our current work, we focus on the mechanisms that reg-
ulate fi brinolysis after injury. Our previous studies demonstrated a 
correlation between fi brin deposition and expression of p75 neuro-
trophin receptor (p75NTR) after nerve injury (Akassoglou et al., 
2002). Up-regulation of p75NTR is observed in MS (Dowling 
et al., 1999), stroke (Park et al., 2000), and spinal cord (Beattie 
et al., 2002) and sciatic nerve injury (Taniuchi et al., 1986), 
all of which are associated with fi brin deposition. p75NTR is also 
expressed in non-neuronal tissues (Lomen-Hoerth and Shooter, 
1995) and is up-regulated in non-nervous system diseases asso-
ciated with defects in fi brin degradation, such as atherosclerosis 
(Wang et al., 2000), melanoma formation (Herrmann et al., 
1993), lung infl ammation (Renz et al., 2004), and liver disease 
(Passino et al., 2007). p75NTR has been primarily characterized 
as a modulator of cell death (Wang et al., 2000) and differentia-
tion (Passino et al., 2007) in non-neuronal tissues. The expres-
sion of p75NTR by cell types such as smooth muscle cells and 
hepatic stellate cells, which actively participate in tissue repair 
by migration, and secretion of ECM and extracellular proteases, 
raises the possibility for a functional role of p75NTR in disease 
pathogenesis that extends beyond apoptosis and differentiation.
We fi nd that p75NTR is involved in the regulation of proteo-
lytic activity and fi brin degradation. Mice defi cient for p75NTR 
(Lee et al., 1992) show increased proteolytic activity and de-
creased fi brin deposition in two disease models: sciatic nerve 
injury and lung fi brosis. p75NTR regulates proteolytic activity by 
simultaneously down-regulating tPA and up-regulating PAI-1 
via a novel cAMP/PKA pathway. p75NTR decreases cAMP via 
interaction with the cAMP-specifi c phosphodiesterase (PDE) 
isoform PDE4A4/5. This is of particular note, as selective PDE4 
inhibitors have an anti-infl ammatory action and have potential 
therapeutic utility in infl ammatory lung disease, as well as in a 
wide range of neurologic diseases such as depression, spinal 
cord injury, MS, and stroke (Gretarsdottir et al., 2003; Nikulina 
et al., 2004; Houslay et al., 2005). Overall, the regulation of 
plasminogen activation by p75NTR identifi es a novel pathogenic 
mechanism whereby p75NTR interacts with PDE4A4/5 to de-
grade cAMP and thus perpetuates scar formation that could 
possibly render the environment hostile for tissue repair.
Results
Fibrin deposition is reduced in p75NTR−/− mice
To examine whether p75NTR regulates fi brin deposition in the 
sciatic nerve we compared fi brin levels in wild-type (wt) and 
p75NTR−/− mice after injury. In wt mice, there is a dramatic 
 increase of fi brin deposition (Fig. 1 c) and p75NTR expression 
(Fig. 1 d) after injury, when compared with uninjured nerves 
(Fig. 1, a and b). In contrast, p75NTR−/− mice show reduced fi brin 
deposition after injury (Fig. 1 e). Quantifi cation of immuno-
blots reveals that p75NTR−/− mice have decreased fi brin by three-
fold 3 d and fourfold 8 d after injury (Fig. 1 g). Quantifi cation 
of fi brin immunostaining also reveals that p75NTR−/− mice have 
signifi cantly decreased fi brin (Fig. 1 h, P < 0.003). These re-
sults suggest that loss of p75NTR decreases the levels of fi brin in 
the sciatic nerve after injury.
p75NTR regulates expression of tPA 
in the sciatic nerve after crush injury
Analysis of total fi brinogen levels were similar in the plasma of 
wt and p75NTR−/− mice (unpublished data), suggesting the de-
crease in fi brin deposition is not the result of hypofi brinogenemia. 
Because fi brin removal depends on proteolytic activity (Bugge 
et al., 1996), we hypothesized that the decreased fi brin in the 
p75NTR−/− mice refl ects an up-regulation of the proteolytic activity. 
p75NTR−/− mice have increased proteolytic activity (Fig. 2 b) 
Figure 1. Fibrin deposition is reduced in the 
sciatic nerve of p75NTR−/− mice. Immunohisto-
chemistry for fi brin on uninjured wt (a) and 4 d 
after sciatic nerve crush injury wt (c) and 
p75NTR−/− mice (e). Immunohistochemistry for 
p75NTR on uninjured wt (b) and 4 d after sciatic 
nerve crush injury wt (d) and p75NTR−/− mice (f). 
Representative images are shown from n = 
20 wt and n = 20 p75NTR−/− mice. (g) Western 
blot for p75NTR and fi brin on sciatic nerve ex-
tracts from uninjured wt, and wt and p75NTR−/− 
mice 3 and 8 d after injury. Myosin serves as 
loading control. Western blots were performed 
three times. A representative blot is shown. 
(h) Quantifi cation of fi brin deposition shows 
signifi cant decrease for fi brin in p75NTR−/− 
mice (n = 5), when compared with wt mice 
(n = 4). Bar graph represents means ± SEM 
(P < 0.003; by t test). Bar, 25 μm. 
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when compared with wt mice (Fig. 2 a) that is statistically sig-
nifi cant (Fig. 3 i, P < 0.05). Uninjured nerves exhibit minimal 
proteolytic activity (Fig. 2 i), as expected (Akassoglou et al., 
2000). Injured p75NTR−/− sciatic nerves do not show lysis of fi brin 
in the absence of plasminogen (Fig. 2 c), suggesting that the 
proteolytic activity is plasminogen dependent.
The tPA/plasmin system regulates fi brin clearance after 
nerve injury (Akassoglou et al., 2000). A specifi c tPA inhibitor, 
tPASTOP, blocks proteolytic activity in p75NTR−/− mice (Fig. 2 d). 
p75NTR is strongly activated by withdrawal of axons (Lemke and 
Chao, 1988) and its expression correlates with proliferating, 
non-myelin producing Schwann cells (SCs) (Zorick and Lemke, 
1996). After sciatic nerve injury both p75NTR (Fig. 2 e, red) 
and tPA (Fig. 2 e, green) increase when compared with un-
injured controls (Fig. 2 j), but show little colocalization (Fig. 2, 
e and h), suggesting that p75NTR-reexpressing SCs do not ex-
press tPA. Expression of tPA (Fig. 2 k, red) and p75NTR (Fig. 2 l, 
red) in SCs is confi rmed using double immunofl uorescence 
with the SC marker S100 (Fig. 2, k and l; green).
Genetic loss of tPA rescues the effects 
of p75NTR defi ciency
To examine genetically whether the increased proteolytic activ-
ity in the p75NTR−/− mice was due to tPA, we crossed p75NTR−/− 
mice with tPA−/− mice and generated p75NTR−/−tPA−/− double-
knockout mice. p75NTR−/− mice show a decrease in fi brin depo-
sition (Fig. 3 b) and an increase in proteolytic activity (Fig. 3 f), 
compared with wt control mice (Fig. 3, a and e, respectively). 
In contrast, p75NTR−/−tPA−/− mice show increased fi brin deposi-
tion (Fig. 3 c) when compared with p75NTR−/− mice (Fig. 3 b) 
and no evidence of proteolytic activity (Fig. 3 g). As a control, 
tPA−/− mice also show no evidence of proteolytic activity after 
sciatic nerve crush injury (Fig. 3 h), as described previously 
(Akassoglou et al., 2000). Quantifi cation of proteolytic activity 
is shown in Fig. 3 i. The evidence derived from the genetic de-
pletion of tPA in the p75NTR−/− mice (p75NTR−/−tPA−/− mice, 
Fig. 3 g) are in accordance with the pharmacologic inhibition of 
tPA activity in the p75NTR−/− sciatic nerve using tPASTOP (Fig. 
2 d). Overall, these results suggest that up-regulation of proteo-
lytic activity in the sciatic nerve of p75NTR−/− mice is due to up-
regulation of tPA.
p75NTR−/− SCs show increased expression 
of tPA and increased fi brinolysis
Because SCs are a major source for tPA after injury, we isolated 
primary SCs from wt and p75NTR−/− mice and cultured them on 
a three-dimensional (3D) fi brin gel. Wt SCs, which express high 
levels of p75NTR, form a monolayer on the fi brin gel (Fig. 4 a). 
In contrast, p75NTR−/− SCs degrade the fi brin gel (Fig. 4 b) and 
show a 2.7-fold increase of fi brin degradation (Fig. 4 c). 
p75NTR−/− SCs show a sixfold increase in tPA levels, when com-
pared with wt SCs (Fig. 4 d; P < 0.01). These results suggest 
that p75NTR down-regulates tPA activity and blocks fi brin degra-
dation in SCs in vitro.
Expression of p75NTR inhibits tPA 
and fi brinolysis
After fi nding a biological function for p75NTR in the regulation 
of tPA using SCs and sciatic nerves from p75NTR−/− mice, we 
used stable and transient transfections of p75NTR as well as 
Figure 2. p75NTR regulates expression of tPA in the sciatic nerve after crush injury. In situ zymography in the presence of plasminogen on wt (a) and 
p75NTR−/− (b) mice and in the absence of plasminogen (c) or in the presence of plasminogen and tPASTOP (d) in p75NTR−/− mice. Arrows indicate the lytic 
zone. Double immunofl uorescence for tPA (green) or p75NTR (red) on wt (e and h), p75NTR−/− (f) and p75NTR−/−tPA−/− mice (g). Uninjured wt sciatic nerve 
exhibits minimal proteolytic activity (i) and minimal tPA and p75NTR immunoreactivity (j). Zymographies have been performed on n = 10 wt and n = 10 
p75NTR−/− mice. Representative images are shown. tPA (k) and p75NTR (l) expression in SCs was verifi ed by double immunofl uorescence with an S100 (SC 
marker) antibody. Arrows indicate double-positive cells (k and l, yellow). The experiment was repeated at two different time points (4 and 8 d after crush 
 injury) in n = 4 mice per genotype per time point and representative images are shown. Bar: 400 μm (a –d, i), 150 μm (e–g, j), 20 μm (h, k, and l). 
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siRNA against p75NTR to test the properties of p75NTR in heterol-
ogous systems. To examine whether p75NTR could inhibit fi brin 
degradation, we fi rst used NIH3T3 fi broblasts stably transfected 
with p75NTR that exhibit high levels of p75NTR (105 receptors/
cell) (Hsu and Chao, 1993). NIH3T3 cells on a 3D fi brin gel 
degrade fi brin (Fig. 5 a), whereas NIH3T3p75NTR cells do not 
(Fig. 5 b). Expression of p75NTR inhibits fi brin degradation by 
12-fold (Fig. 5 c; P < 0.001). NIH3T3 cells form lytic areas 
(Fig. 5 d), whereas NIH3T3p75NTR cells grow uniformly on fi brin 
(Fig. 5 e). NIH3T3 cells fully degrade the plasmin substrate 
 casein (Fig. 5 f) but NIH3T3p75NTR cells do not degrade casein 
(Fig. 5 g), suggesting impaired proteolysis in NIH3T3p75NTR cells. 
Aprotinin, a general inhibitor of serine proteases, completely 
inhibits fi brin degradation by NIH3T3 cells (not depicted). 
In fi broblasts both tPA and uPA are involved in activation of 
plasminogen and fi brin degradation. tPA activity is signifi cantly 
decreased in the NIH3T3p75NTR cells (Fig. 5 h). In contrast, 
 expression of p75NTR has no effect on uPA activity (Fig. 5 i).
tPA is a transcriptionally regulated immediate-early gene 
(Qian et al., 1993). Indeed, expression of p75NTR down-regulates 
tPA transcripts (Fig. 5 j). In addition, mRNA of PAI-1 is also up-
regulated in NIH3T3p75NTR cells (Fig. 5 j). Real-time quantita-
tive PCR shows a 10.1-fold decrease in tPA mRNA, a fourfold 
increase in PAI-1 mRNA, and a twofold decrease in uPA mRNA 
in NIH3T3p75NTR cells. Upon expression of p75NTR, the decrease 
of uPA RNA does not affect uPA activity (Fig. 5 i). In contrast, 
the decrease of tPA RNA in NIH3T3p75NTR cells results in a 
 corresponding decrease in tPA activity (Fig. 5 h; P < 0.01). 
Figure 3. Loss of tPA rescues the effects of p75NTR defi ciency in plasminogen activation and fi brin deposition in the sciatic nerve. Increased fi brin deposition 
in the crushed sciatic nerve of p75NTR−/−tPA−/− mice (c), when compared with crushed p75NTR−/− sciatic nerve (b). Wt (a) and tPA−/− (d) nerves are used for 
control. In situ zymography shows lack of proteolytic activity in the crushed p75NTR−/−tPA−/− sciatic nerves (n = 5) (g), when compared with crushed p75NTR−/− 
sciatic nerves (n = 20) (f). Crushed wt (e) and tPA−/− (h) nerves are used for control. Fibrin immunostainings and zymographies were performed on n = 5 
p75NTR−/−tPA−/−, n = 20 p75NTR−/−, n = 20 wt, n = 5 tPA−/− mice. Representative images are shown. (i) Quantifi cation of proteolytic activity 4 d after crush 
injury shows statistically signifi cant increase for proteolytic activity in p75NTR−/− mice. Quantifi cation results are based on n = 5 p75NTR−/−, n = 5 p75NTR−/− 
tPA−/−, n = 5 tPA−/− and n = 4 wt mice. Bar graph represents means ± SEM (*, P < 0.05; by ANOVA). Bar: 50 μm (a–d), 300 μm (e–h). 
Figure 4. p75NTR-mediated regulation of tPA and fi brinolysis in SCs. 
Primary SC cultures from wt (a) or p75NTR−/− mice (b) on a 3D fi brin gel. 
Arrowheads indicate the border of fi brin degradation. Quantifi cation of 
 fi brin degradation (c) and tPA activity (d) from wt and p75NTR−/− SCs. 
Experiments were performed three times in duplicates. Representative im-
ages are shown. Bar graph represents means ± SEM (P < 0.01; by t test). 
Bar, 130 μm.
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After injury, sciatic nerves of p75NTR−/− mice show a fourfold in-
crease of tPA RNA when compared with wt (Fig. 5 k). More-
over, p75NTR−/− mice show an increase in tPA RNA in primary 
cerebellar granule neurons (CGNs) (Fig. S1 c, available at 
http://www.jcb.org/cgi/content/full/jcb.200701040/DC1), and 
increased proteolytic activity in the cerebellum (Fig. S1, a and b). 
Overall, these data suggest that expression of p75NTR inhibits the 
tPA/plasmin system both in vivo in the cerebellum and after sci-
atic nerve injury, as well as in vitro in primary neurons, SCs, as 
well as fi broblasts.
p75NTR regulates tPA and PAI-1 
via a PDE4/cAMP/PKA pathway
Transcriptional regulation of tPA depends on the cAMP/PKA 
pathway (Medcalf et al., 1990). Indeed, elevation of cAMP, 
 using dibutyryl-cAMP (db-cAMP), overcomes the inhibitory 
effect of p75NTR (Fig. 6 a). Moreover, cAMP elevation, elicited 
using the general PDE inhibitor IBMX, elevates tPA activity in 
NIH3T3p75NTR to the levels seen in NIH3T3 cells (Fig. 6 b). 
IBMX does not affect basal levels of tPA in NIH3T3 cells (Fig. 6 b). 
These data suggest that PDE activity is required for the p75NTR-
induced tPA decrease.
PKA activity is decreased in NIH3T3p75NTR cells (Fig. 6 c, 
lanes 3 and 4) compared with NIH3T3 cells (Fig. 6 c, lanes 1 
and 2), suggesting that p75NTR expression reduces PKA activity. 
KT5720, a specifi c PKA inhibitor, decreases tPA activity in 
NIH3T3 cells (Fig. 6 b). Because the cAMP/PKA pathway 
 enhances tPA transcription and suppresses PAI-1 secretion 
(Santell and Levin, 1988), we tested whether the cAMP/PKA 
pathway infl uences the p75NTR regulation of tPA and PAI-1. 
Forskolin-induced cAMP elevation increases, whereas KT5720-
induced PKA inhibition decreases tPA RNA in NIH3T3 cells 
(Fig. 6 d). Forskolin treatment of NIH3T3p75NTR cells also in-
creases both tPA RNA (Fig. 6 d) and activity (not depicted), 
whereas forskolin decreases PAI-1 RNA in both NIH3T3 and 
NIH3T3p75NTR cells (Fig. 6 e).
Similar to NIH3T3 cells, elevation of cAMP increases the 
activity of tPA in both wt and p75NTR−/− SCs (Fig. 6 f). Brain-
 derived neurotrophic factor (BDNF)/TrkB signaling has been 
shown to regulate tPA in primary cortical neurons (Fiumelli 
et al., 1999). In contrast to cortical neurons, SCs are known to 
express minute levels of TrkB but high levels of p75NTR (Cosgaya 
et al., 2002). We show here that treatment of SCs with either 
BDNF or nerve growth factor (NGF) has no effect on tPA (Fig. 6 f). 
Similar results are obtained after treatment of SCs with pro-
NGF, the high-affi nity ligand of p75NTR (Lee et al., 2001) (un-
published data). In addition, in NIH3T3 and NIH3T3p75NTR 
cells, which do not express Trk receptors, the p75NTR-mediated 
suppression of tPA activity occurs independent of neurotrophins 
or serum (unpublished data). In accordance, in NIH3T3 cells 
transient expression of the intracellular domain (ICD) of p75NTR 
decreases tPA similar to the full-length (FL) p75NTR (Fig. 6 g). 
Figure 5. Expression of p75NTR regulates tPA, PAI-1, and fi brinolysis in fi broblasts. 3D fi brin gel degraded by NIH3T3 (a), but not by NIH3T3p75NTR cells (b). 
(c) Quantifi cation of fi brin degradation. Experiments were performed seven times in duplicates. Phase-contrast microscopy shows lytic zones in NIH3T3 (d), 
but not in NIH3T3p75NTR cultures (e). Zymography shows degradation of casein by NIH3T3 cells (f), whereas NIH3T3p75NTR cells do not degrade 
casein (g). Quantifi cation of tPA (h) and uPA (i) activity in supernatants from NIH3T3 and NIH3T3p75NTR cultures. Experiments were performed fi ve times in 
duplicates. (j) RT-PCR analysis for tPA, PAI-1, uPA, and GAPDH on cDNA derived from NIH3T3 and NIH3T3p75NTR cells. (k) RT-PCR analysis for tPA and 
GAPDH on cDNA derived from uninjured wt, and wt or p75NTR−/− mice three days after nerve injury. Bar graphs represent means ± SEM (statistics by 
t test). Bar: 1.2 cm (a and b), 130 μm (d–g).
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These data suggest that neurotrophin/p75NTR signaling is not in-
volved in the regulation of tPA in SCs and fi broblasts and that 
regulation of tPA by p75NTR is independent of neurotrophins.
p75NTR decreases cAMP via PDE4
Because the effects of p75NTR were overcome by elevating 
cAMP, we examined whether p75NTR reduced cAMP levels. 
 Indeed, cAMP is decreased 7.8-fold in NIH3T3p75NTR cells 
(Fig. 7 a; P < 0.0001). Transient expression of p75NTR in NIH3T3 
cells decreases levels of cAMP (Fig. 7 b; P < 0.0005).
Furthermore, siRNA knockdown against p75NTR leads to in-
creased cAMP levels in both NIH3T3p75NTR cells (Fig. 7, c and e; 
P < 0.02) and primary SCs (Fig. 7, d and f; P < 0.03). 
NIH3T3 cells transiently transfected with p75NTR express fi ve-
fold less p75NTR than the stably transfected NIH3T3p75NTR cells 
(unpublished data). Differences in expression between stably 
and transiently transfected cells may account for the differ-
ences in the fold-decrease of cAMP and tPA between these two 
systems. Moreover, immunostaining with an antibody against 
cAMP shows increased cAMP in injured sciatic nerves from 
p75NTR−/− mice (Fig. 7, g and h). In neurons BDNF elevates 
cAMP exclusively via TrkB (Gao et al., 2003). In NIH3T3p75NTR 
cells, which do not express TrkB, stimulation with NGF or 
BDNF does not affect the p75NTR-mediated suppression of 
cAMP (Fig. S2). Similarly, inhibition of neurotrophins by 
Fc-p75NTR or BDNF by Fc-TrkB does not alter cAMP levels in 
NIH3T3p75NTR cells (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200701040/DC1). In accordance, transient 
expression of the ICD of p75NTR decreases cAMP similar to the 
FL p75NTR in NIH3T3 cells (Fig. 7 b). Overall, these data sug-
gest a neurotrophin-independent PDE4/cAMP pathway down-
stream of p75NTR, which consequently leads to decreases in 
extracellular proteolysis.
Down-regulation of cAMP can be mediated either by in-
hibition of cAMP synthesis via the action of Gi, a G protein that 
inhibits adenylyl cyclase or via the action of PDEs. Treatment 
of cells with pertussis toxin (PTX) that blocks interactions be-
tween the Gi and G protein coupled receptors, does not rescue 
the p75NTR-mediated down-regulation of cAMP (Fig. 7 a; 
P > 0.5). In contrast, the PDE inhibitor IBMX resulted in sig-
nifi cant increase of cAMP in the NIH3T3p75NTR cells when 
compared with control NIH3T3p75NTR cells (Fig. 7 a; P < 
0.000001). Use of specifi c chemical inhibitors for PDE iso-
forms shows that only rolipram, a specifi c inhibitor of PDE4, 
signifi cantly increases cAMP levels in NIH3T3p75NTR cells 
(Fig. 7 a; P < 0.000001) to the levels of NIH3T3 cells (Fig. 7 a; 
P = 0.051), suggesting that the p75NTR-induced cAMP decrease 
is mediated via PDE4.
Figure 6. p75NTR regulates tPA and PAI-1 via a PDE4/cAMP/PKA pathway. (a) db-cAMP induces fi brinolysis in NIH3T3p75NTR cells. (b) IBMX increases 
tPA activity of NIH3T3p75NTR cells to the levels of NIH3T3 cells. Inhibition of PKA by KT5720 shows decrease of tPA activity in both NIH3T3 and 
NIH3T3p75NTR cells (P < 0.0001). (c) PKA activity assay shows decrease of PKA in NIH3T3p75NTR cells. (d) Forskolin increases tPA mRNA in NIH3T3 and 
NIH3T3p75NTR cells. Inhibition of PKA by KT5720 decreases tPA transcript. (e) Quantifi cation of PAI-1 mRNA changes by real time PCR shows a fourfold 
increase of PAI-1 mRNA in NIH3T3p75NTR cells compared with NIH3T3 cells. (f) Forskolin increases tPA activity in both wt (P<0.001) and p75NTR−/− (P < 
0.00001) SCs. NGF and BDNF do not affect activity of tPA (P > 0.8 and P > 0.3, respectively). (g) Transient overexpression of FL p75NTR or p75 ICD 
leads to decreased levels of tPA in NIH3T3 cells. Experiments were performed at least 5 times in duplicates. *, P < 0.0001; **, P < 0.05; ***, P < 0.01. 
NS: non-signifi cant. Bar graphs represent means ± SEM (statistics by ANOVA).
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p75NTR interacts with PDE4A4/5 
and targets cAMP degradation 
to the membrane
Recruitment of PDE4 to subcellular structures such as the 
plasma membrane concentrates the activity of PDEs and re-
duces PKA activity by enhancing degradation of cAMP (Brunton, 
2003; Houslay and Adams, 2003). We therefore examined 
whether p75NTR regulates cAMP via recruitment of PDE4. In 
NIH3T3p75NTR cells, p75NTR coimmunoprecipitates (co-IPs) with 
endogenous PDE4A (Fig. 8 a). No association is observed with 
the other three PDE4 sub-families, namely PDE4B, PDE4C, 
or PDE4D (unpublished data), suggesting that the effect was 
PDE4A specifi c. Based on the molecular weight of PDE4A at 
109 kD, we determined that p75NTR co-IPs with the PDE4A5 
isoform. Endogenous co-IP in CGNs (Fig. S3 a, available at 
http://www.jcb.org/cgi/content/full/jcb.200701040/DC1) and in 
injured sciatic nerve (Fig S3 b) shows that p75NTR and PDE4A5 
interact at endogenous expression levels. Analysis of lysates 
shows that the levels of PDE4A are similar in NIH3T3 and NI-
H3T3p75NTR cells (Fig. S3 c). These results show that p75NTR 
forms a complex with PDE4A5.
A functional consequence of the p75NTR–PDE4A5 inter-
action would be recruitment of PDE4A5 to the membrane re-
sulting in decreased membrane-associated cAMP/PKA signaling. 
To investigate whether p75NTR reduces membrane-associated 
PKA activity, we modifi ed the genetically encoded A-kinase 
activity reporter, AKAR2 (Zhang et al., 2005) and generated 
pm-AKAR2.2, a membrane-targeted fl uorescent reporter of 
PKA activity that generates a change in fl uorescence reso-
nance energy transfer (FRET) when it is phosphorylated by 
PKA in living cells (Fig. S4 a). As expected, NIH3T3 cells 
show a dramatic emission ratio change for the pm-AKAR2.2 
in response to forskolin (Fig. 8 b). In contrast, NIH3T3p75NTR 
cells show an attenuated response, revealing reduced PKA 
activity at the plasma membrane (Fig. 8 b). Transient trans-
fection of p75NTR confi rmed the results observed in the stable 
NIH3T3p75NTR cells using the latest generation of plasma 
 membrane–specifi c PKA biosensor AKAR3 (Allen and Zhang, 
2006) (Fig. S4 b, available at http://www. jcb.org/cgi/content/
full/jcb.200701040/DC1). As expected, increased cAMP degra-
dation at the plasma membrane results in decreased intracel-
lular cAMP (Fig. S4 c; Fig. 7, a and b). Overall, our results 
showing reduced membrane-associated PKA activity upon 
expression of p75NTR suggest that p75NTR targets cAMP deg-
radation to the membrane via its interaction with PDE4A5.
To verify the specifi city of p75NTR–PDE4A5 association, a se-
ries of mapping studies were conducted using deletion mutants. 
PDE4A5 interacts with FL p75NTR, as well as deletions ∆3, ∆62, 
Figure 7. p75NTR decreases intracellular cAMP via PDE4. 
(a) cAMP levels in NIH3T3 and NIH3T3p75NTR cells show 
a reduction of cAMP in NIH3T3p75NTR cells, as compared 
with NIH3T3 cells. Treatment with PTX, IBMX, specifi c 
 inhibitors for PDE1, PDE2, PDE3, and PDE4 (rolipram) 
shows that only IBMX (IC50 for PDE4 2–50 μM) and ro-
lipram (IC50 for PDE4 0.8 μM) (P < 0.0001) increase 
levels of cAMP in NIH3T3p75NTR cells to the levels of 
NIH3T3 cells. (b) Transient overexpression of FL p75NTR or 
p75 ICD leads to decreased levels of cAMP in NIH3T3 
cells. (c) siRNA mediated knockdown of p75NTR levels in 
NIH3T3p75NTR cells leads to increased levels of cAMP. 
(d) siRNA mediated knockdown of p75NTR in primary rat 
Schwann cells leads to increased levels of cAMP. p75NTR 
levels after siRNA knock down in duplicate samples of 
NIH3T3p75NTR cells (e) and SCs (f). Immunostaining to de-
tect cAMP in injured sciatic nerve reveals increased cAMP 
immunoreactivity in the sciatic nerve of p75NTR−/− mice (h) 
when compared with wt controls (g). Experiments were 
performed four times in duplicate. Bar graphs represent 
means ± SEM (statistics by ANOVA or t test). 
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∆83, but not a deletion missing the distal 151 amino acids, ∆151 
(Fig. 8 c), suggesting that the interaction between p75NTR and 
PDE4A5 occurs in the juxtamembrane region of p75NTR, requir-
ing sequences between residues 275 and 343. To explain the 
specifi city of the interaction of p75NTR with a single PDE4 iso-
form, we reasoned that p75NTR would interact with a unique region 
of PDE4A5 that is not present in other PDE4s. Although the 
PDE4 isoforms are highly homologous, PDE4A5 contains a 
unique C-terminal region with a yet unknown biological function 
(Houslay and Adams, 2003). Co-IP experiments in HEK293 cells 
us ing the PDE4A4δCT mutant that is missing the C-terminal region 
(aa 721–886) abolishes the interaction with p75NTR (Fig. 8 d).
To examine whether p75NTR could interact with PDE4A5 in 
a direct manner, we performed in vitro pull-down assays using re-
combinant proteins. A GST fusion protein of p75NTR encoding the 
entire ICD interacts with both recombinant PDE4A5 and its hu-
man homologue PDE4A4 (Fig. 8 e). In contrast, p75NTR ICD does 
not interact with recombinant PDE4D3 (Fig. 8 e). These results 
are in accordance with both the endogenous co-IPs in cells (Fig. 
8, a and c; Fig. S3) and the PDE4A4 mutagenesis data (Fig. 8 d) 
because similar to PDE4A4δCT, PDE4D3 does not contain the 
unique C-terminal domain of PDE4A4/5. We have used peptide 
array technology to defi ne sites of direct interaction in other 
PDE4s (Bolger et al., 2006). Screening a peptide array library 
of overlapping 25-mer peptides that scanned the sequence of 
PDE4A4 with GST-ICD p75NTR identifi ed interactions with the 
LR1 domain, whose sequence is unique to the PDE4A subfamily 
(peptides 40 and 41, aa 191–220), and also to a sequence within 
the catalytic domain (peptides 135 and 136, aa 671–700). How-
ever, the strongest interaction was observed with sequences within 
the C-terminal region of PDE4A4 (peptides 172 and 173, aa 856–
885). Alanine scanning mutagenesis shows that substitution of 
C862 abolishes the interaction of p75NTR with the 173 peptide that 
is unique to PDE4A (Fig. 8 g). The p75NTR-interacting sequences 
within the LR1 and C-terminal domains are highly conserved 
 between the human PDE4A4 and the rodent PDE4A5. Indeed, 
peptide array screening for PDE4A5 reveals direct interaction 
with p75NTR similar to that seen for PDE4A4 (unpublished data). 
Overall, these results suggest that the interaction of p75NTR with 
PDE4A4/5 is direct and that sequences within the juxtamembrane 
region of p75NTR and the unique C-terminal region of PDE4A4/5 
are primarily required for the interaction (Fig. 8, a, c–g; Fig. S3).
Figure 8. p75NTR interacts with PDE4A4/5. (a) Endoge-
nous PDE4A5 co-IPs with p75NTR in NIH3T3p75NTR cells. 
Lysates were immunoprecipitated with anti-p75NTR and 
probed with anti-PDE4A or anti-p75NTR. Due to the low 
endogenous levels of PDE4A, higher exposure was ne-
cessary to detect PDE4A5 in the lysates (see Fig. S3 c). 
(b) FRET emission ratio change of NIH3T3 and NIH3T3p75NTR 
cells for the pm-AKAR2.2 in response to forskolin. FRET 
change represents membrane activation of PKA (c) Map-
ping of the p75NTR sites required for interaction with 
PDE4A5. Schematic diagram of HA-tagged p75NTR intra-
cellular deletions. TM, transmembrane domain; DD, death 
domain. Lysates were immunoprecipitated with an anti-
HA antibody and probed with anti-PDE4A or anti-p75NTR. 
(d) Mapping of the PDE4A4 sites required for interaction 
with p75NTR. Schematic diagram of the C-terminal dele-
tion of PDE4A4. Arrow indicates the deletion site. Lysates 
were immunoprecipitated with anti-p75NTR and probed 
with anti-PDE4A or anti-p75NTR. (e) Co-IP of purifi ed, re-
combinant proteins reveals that both PDE4A4 and 
PDE4A5 interact with the ICD of p75NTR, but PDE4D3 
does not. (f) PDE4A4 peptide library screened with re-
combinant GST-p75NTR ICD revealed three distinct do-
mains of PDE4A4 (asterisks in d) that interact with the ICD 
of p75NTR: the LR1 domain (peptides 40 and 41), the cat-
alytic domain (peptides 135 and 136) and the unique C 
terminus (peptides 172 and 173). (g) Alanine scanning 
mutagenesis shows that substitution of C862 abolishes 
the interaction of p75NTR with the 173 peptide that is 
unique to PDE4A. 
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p75NTR regulates plasminogen activation 
and fi brin deposition in a model 
of lipopolysaccharide-induced 
pulmonary fi brosis
Because expression of p75NTR inhibits fi brinolysis in fi broblasts, 
we hypothesized that the role of p75NTR as a modulator of fi brino-
lysis extends to tissues outside of the nervous system that ex-
press p75NTR after injury or disease. Because p75NTR is expressed 
in the lung (Ricci et al., 2004), we compared the levels of fi brin 
in the lung of wt and p75NTR−/− mice in a model of lipopoly-
saccharide (LPS)-induced lung fi brosis (Chen et al., 2004). 
LPS-treated wt mice showed widespread extravascular fi brin 
deposition (Fig. 9 b) and decreased proteolytic activity after 
LPS treatment (Fig. 9 e), when compared with saline-treated wt 
mice (Fig. 9, a and d). In contrast, p75NTR−/− mice show a 2.58-
fold decrease of fi brin immunoreactivity (Fig. 9, c and j) and 
increased proteolytic activity (Fig. 9 f).
Decreased proteolytic activity in the lung after injury de-
pends on the up-regulation of PAI-1 (Idell, 2003). Loss of PAI-1 
protects from pulmonary fi brosis in LPS-induced airway dis-
ease, hyperoxia, and bleomycin-induced fi brosis (Savov et al., 
2003). Because p75NTR increases PAI-1 (Fig. 5 j and Fig. 6 e), we 
examined whether p75NTR regulates expression of PAI-1 in vivo. 
PAI-1 is up-regulated in LPS-treated wt mice (Fig. 9 h) when 
compared with saline-treated wt mice (Fig. 9 g). In contrast, 
LPS-treated p75NTR−/− mice show similar immunoreactivity for 
PAI-1 (Fig. 9 i) as saline-treated wt mice (Fig. 9 g), suggesting 
that p75NTR induces up-regulation of PAI-1 after injury in the lung. 
Western blots show a decrease in PAI-1 in the lungs of p75NTR−/− 
mice (Fig. 9 k). Similar to the p75NTR−/− mice, rolipram reduces 
fi brin deposition in the lung (Fig. S5, a and b; available at http://
www.jcb.org/cgi/content/full/jcb.200701040/DC1) and sciatic 
nerve (Fig. S5, d–f), and decreases PAI-1 in the lung (Fig. S5 c), 
suggesting the involvement of PDE4 in p75NTR-mediated inhibi-
tion of fi brinolysis in vivo. Collectively, our data show that 
p75NTR increases fi brin deposition via a PDE4-mediated inhibi-
tion of plasminogen activation in both LPS-induced lung fi brosis 
and sciatic nerve crush injury. These data suggest a role for 
p75NTR/PDE4 signaling as a general regulator of plasminogen 
activation and fi brinolysis at sites of injury.
Discussion
Our study shows a novel direct interaction of p75NTR with 
PDE4A4/5, a specifi c PDE4 isoform, which results in the regu-
lation of cAMP, a major intracellular signaling pathway, and 
mediates a major biological function of extracellular prote-
olysis and fi brinolysis (Fig. 10). p75NTR is expressed in a wide 
range of tissue injury models, where repair depends upon both 
cell differentiation and ECM remodeling. For example, we re-
cently showed that in the absence of plasminogen the effects of 
p75NTR in tissue repair are protective due to its benefi cial effects 
in cell differentiation (Passino et al., 2007). Similarly, in the 
fl ow-restricted carotid artery model of vascular injury that 
 depends on uPA and not on tPA-mediated fi brinolysis (Kawasaki 
et al., 2001), p75NTR is protective due to the induction of smooth 
Figure 9. p75NTR regulates fi brin clearance in the lung. 
LPS induces fi brin deposition (red) in the wt lung (b), when 
compared with the saline-injected lung (a). Lungs derived 
from p75NTR−/− mice show less fi brin deposition (c). In situ 
zymography after 3 h of incubation shows clearance of 
casein in the lung of saline-injected wt (d), when com-
pared with LPS injected wt lung (e). Lung from LPS-treated 
p75NTR−/− mouse shows enhanced proteolytic activity (f), 
when compared with the wt mouse (e). Immunoreactivity 
for PAI-1 is increased in wt lung derived from LPS-treated 
mouse (h), when compared with saline-treated control (g). 
Lung from LPS-treated p75NTR−/− mouse shows decreased 
PAI-1 (i), when compared with the wt LPS-treated mouse 
(h). (j) Western blot of fi brin precipitation from the lung 
shows an up-regulation of fi brin in the LPS-treated wt lung, 
when compared with the p75NTR−/− lung. (k) Western blot 
for PAI-1 in the lung shows a decrease of PAI-1 in the 
p75NTR−/− lung, when compared with the wt lung. Images 
are representative of n = 10 wt and n = 9 p75NTR−/− 
mice. Western blots have been performed for n = 4 wt 
and n = 4 p75NTR−/− mice. Bar: 150 μm (a–c), 75 μm 
(a–c, inset), 200 μm (d–f), 150 μm (g–i).
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muscle cell apoptosis (Kraemer, 2002). In the sciatic nerve 
p75NTR appears to have a dual role by sustaining fi brin deposi-
tion (our study), and also promoting myelination (Cosgaya et al., 
2002; Song et al., 2006). Examination of functional recovery 
in p75NTR−/− mice after peripheral nerve injury would reveal 
the contribution of p75NTR-mediated ECM remodeling and re-
myelination to the regeneration process. Overall, the biological 
role of p75NTR after tissue injury would probably depend on the 
relative contributions of its role as a regulator of cell death and 
differentiation and its role as an inhibitor of fi brinolysis.
We identify regulation of cAMP as a novel signaling me-
chanism downstream of p75NTR. Previous studies showed that 
β2-adrenergic receptors target degradation of cAMP to the mem-
brane via recruitment of multiple PDE4 isoforms, such as 
PDE4B1, PDE4B2, and PDE4Ds (Perry et al., 2002). Our fi nding 
of interaction between p75NTR and PDE4A4/5 represents the 
fi rst example of recruitment of a single PDE4 isoform to a trans-
membrane receptor. While interaction of β2-adrenergic recep-
tors with PDE4s is mediated via β-arrestin, our study suggests 
that the interaction of p75NTR with PDE4A4/5 could be poten-
tially mediated by direct binding to PDE4A domains, such as 
the C-terminal domain that is unique to this sub-family. In addi-
tion, in co-IP experiments we do not detect an interaction be-
tween p75NTR and β-arrestin (unpublished data). It is possible 
that the unique C-terminal domain of PDE4A could regulate 
isoform-specifi c PDE4 recruitment to subcellular locations. 
Biological roles have been described for PDE4D in ischemic 
stroke (Gretarsdottir et al., 2003) and heart failure (Lehnart et al., 
2005) and for PDE4B in schizophrenia (Millar et al., 2005). Our 
study identifi es a biological function for PDE4A4/5 as a molec-
ular mediator of p75NTR/cAMP/PKA signaling involved in the 
regulation of tPA and fi brinolysis.
In spinal cord injury in rodents, elevation of cAMP via the 
PDE4 inhibitor, rolipram, promotes axonal regeneration and 
functional recovery (Nikulina et al., 2004). In the sciatic nerve, 
reduction of cAMP after injury is attributed primarily to up-
 regulation of PDE4 by SCs (Walikonis and Poduslo, 1998). 
Based on our fi ndings, it is possible that reexpression of p75NTR 
after injury could contribute to the activation of PDE4 and 
down-regulation of cAMP. BDNF, but not NGF, increases 
cAMP in neurons via TrkB (Gao et al., 2003). Moreover, BDNF/
TrkB signaling overcomes the inhibition of nerve regeneration 
by myelin proteins via inhibition of PDE4 (Gao et al., 2003). 
We provide the fi rst evidence for p75NTR in the regulation of 
cAMP by using genetic depletion, siRNA knockdown or up-
regula tion of the p75NTR. Our results suggest that p75NTR might 
exert the opposite function as Trk receptors by recruiting 
PDE4A4/5 and decreasing cAMP. Interestingly, PDE4A has 
been detected as the predominant PDE4 isoform at the cortico-
spinal tract (Cherry and Davis, 1999). Because p75NTR can act 
as a coreceptor for NogoR, a mediator of the inhibition of 
nerve regeneration, PDE4A interaction with p75NTR could play 
an inhibitory role in nerve regeneration by competing with neuro-
trophin signaling via Trk receptors.
It is possible that the increased expression of p75NTR by 
neurons, glia, and brain endothelial cells could regulate the tem-
poral and spatial pattern of tPA expression during brain injury 
or infl ammation. p75NTR might also be upstream of other non-
 fi brinolytic functions associated with tPA, such as neurodegener-
ation, synaptic plasticity, and long-term potentiation (Samson 
and Medcalf, 2006). Given the dependence of p75NTR func-
tions on the availability of ligands and coreceptors (Teng and 
Hempstead, 2004; Reichardt, 2006), further analysis will deter-
mine the role of p75NTR in extracellular proteolysis and ECM 
remodeling in different cellular systems. We show that expression 
of p75NTR can inhibit tPA in the absence of neurotrophin ligands. 
Constitutive expression of p75NTR may signal in a neurotrophin-
independent manner to induce neuronal apoptosis (Rabizadeh 
et al., 1993), activation of Akt (Roux et al., 2001), and RhoGTPase 
(Yamashita et al., 1999). The regulation of cAMP identifi ed 
here is an effect of expression of p75NTR that does not appear 
to depend on neurotrophin signaling. The cellular distribution 
of PDE4A4/5 would determine the involvement of p75NTR 
in the regulation of cAMP. It is possible that non-neurotrophin 
ligands that bind directly to p75NTR, such as β-amyloid (Teng 
and Hempstead, 2004), as well as the myelin/NogoR p75NTR–
dependent inhibitors of nerve regeneration (Filbin, 2003), are able 
to regulate both cAMP and plasminogen activation by p75NTR. 
Because cAMP analogues decrease expression of p75NTR (Baron 
et al., 1997), it is possible that p75NTR by decreasing cAMP con-
tributes to the positive regulation of its expression. Because PKA 
phosphorylates p75NTR and regulates its translocation to lipid 
rafts (Higuchi et al., 2003), p75NTR via regulation of PKA might 
regulate its own subcellular localization. Given the multiple 
genes regulated by cAMP and PKA, other cellular functions 
may be regulated by p75NTR/cAMP signaling.
Figure 10. Proposed model for the role of p75NTR in the 
cAMP-mediated plasminogen activation. p75NTR interacts 
with PDE4A4/5 resulting in degradation of cAMP and 
thus a reduction of PKA activity. Decrease in cAMP re-
duces expression of tPA and increases PAI-1, resulting in 
reduction of plasmin and plasmin-dependent extracellular 
proteolysis. Reduction of plasmin results in reduced fi brin 
degradation and ECM remodeling. Because plasmin can 
proteolytically modify nonfi brin substrates, such as growth 
factors and cytokines, this mechanism may be upstream of 
various cellular functions. 
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NGF/p75NTR signaling has been suggested to enhance lo-
cal neurogenic infl ammation to exacerbate pulmonary disease 
(Renz et al., 2004). Our study suggests an additional pathway 
for p75NTR as a regulator of expression of PAI-1 and a mediator 
of fi brosis. p75NTR in the lung is detected mainly in basal epithe-
lial cells of bronchioles (unpublished data). Similar to p75NTR, 
PAI-1 is expressed by bronchial epithelial cells (Savov et al., 
2003) and its expression results in an antifi brinolytic environ-
ment within the airway wall. Fibrin regulates both infl ammation 
and airway remodeling (Idell, 2003; Savov et al., 2003). It is 
therefore possible that p75NTR-mediated regulation of PAI-1 via 
PDE4 could infl uence infl ammatory and tissue repair processes 
in pulmonary disease. Although in chronic obstructive pulmo-
nary disease the PDE4A4 isoform is specifi cally up-regulated 
(Barber et al., 2004) and considered a pharmacologic target 
(Houslay et al., 2005), all available inhibitors target the com-
mon catalytic domain of all PDE4 isoforms resulting in un-
wanted side-effects. Our study suggests that the p75NTR/PDE4A4 
interaction could be a potential therapeutic target that will 
achieve the specifi c inhibition of a single PDE4 isoform and 
may have therapeutic potential.
Collectively, we have identifi ed a novel cAMP-dependent 
signaling pathway initiated by p75NTR that specifi cally regu-
lates plasminogen activity and scar formation after sciatic nerve 
and lung injury. Though p75NTR is responsible for a variety of 
cell survival and death decisions (Chao, 2003), our data has re-
vealed an unrecognized property of this receptor to regulate the 
degradation of cAMP. This property provides a potential mech-
anism to account for how p75NTR acts at sites of injury to pro-
mote ECM remodeling. The impact of high levels of p75NTR 
expression upon inhibition of extracellular proteolysis indi-
cates that the detrimental effects of p75NTR extend beyond cell 
growth and axon inhibition. Finally, the dramatic inhibitory 
 effect of p75NTR signaling on plasminogen activation sug-
gests that the p75NTR/PDE4A4 interaction represents a novel 
target for therapeutic intervention in both neuronal and non-
neu ronal tissues.
Materials and methods
Animals, sciatic nerve crush, and induction of lung fi brosis
p75NTR−/− mice (Lee et al., 1992) and tPA−/− mice (Carmeliet et al., 1994) 
were in C57Bl/6 background and purchased from The Jackson Laboratory. 
Double p75NTR−/−tPA−/− mice were generated by crossing p75NTR−/− mice 
with tPA−/− mice. C57Bl/6J mice were used as controls. Sciatic nerve 
crush was performed as described previously (Akassoglou et al., 2000). 
Lung fi brosis was induced as described previously (Chen et al., 2004). 
For the rolipram treatments, mice were administered 5 mg/kg rolipram 
(Calbiochem) before the LPS injection as described previously (Miotla 
et al., 1998). Mice were killed 4.5 h after LPS or saline administration. For 
rolipram treatment after sciatic nerve injury, mice were injected with roli-
pram (1 mg/kg) once daily for 8 d until tissue was harvested and pro-
cessed for immunostaining.
Immunohistochemistry
Immunohistochemistry was performed as described in Akassoglou et al. 
(2002). Primary antibodies were sheep anti –human fi brin(ogen) (1:200; 
US Biologicals), rabbit anti–human tPA (1/300; Molecular Innovations), 
rabbit anti-p75NTR clone 9651, (1:1,000), goat anti-p75NTR (1/200; Santa 
Cruz Biotechnology, Inc.), rabbit anti–mouse PAI-1 (1:500; a gift from 
 David Loskutoff, Scripps Research Institute, La Jolla, CA), and mouse anti-
S100 (1:200; Neomarkers). For immunofl uorescence, secondary antibodies 
were anti–rabbit FITC and anti–goat Cy3 (1:200; Jackson Immunochemicals). 
Images were acquired with an Axioplan II epifl uorescence microscope 
(Carl Zeiss MicroImaging, Inc.) using dry Plan-Neofl uar lenses using 10× 
0.3 NA, 20× 0.5 NA, or 40× 0.75 NA objectives equipped with 
Axiocam HRc digital camera and the Axiovision image analysis system.
Immunoblot
Immunoblot was performed as described previously (Akassoglou et al., 
2002). Antibodies used were rabbit anti-p75NTR clones 9992 and 9651 
(1:5,000), mouse anti-fi brin (1:500; Accurate Chemical & Scientifi c 
Corp.), rabbit anti-myosin (1:1,000; Sigma-Aldrich), rabbit anti-GAPDH 
(1:5,000; Abcam) and rabbit anti-PAI-1 (1:5,000; a gift of David Loskutoff). 
Quantifi cation was performed on the Scion NIH Imaging Software. Fibrin 
precipitation and quantifi cation from lung tissues was performed exactly as 
described previously (Ling et al., 2004).
Co-IP
Co-IP was performed as described previously (Khursigara et al., 1999). 
Cell lysates were prepared in 1% NP-40, 200 mM NaCl, 1 mM EDTA, and 
20 mM Tris-HCl, pH 8.0. IP was performed with an anti-p75NTR antibody 
(9992) and immunoblot with anti-PDE4A, PDE4B, PDE4C, and PDE4D 
(Fabgennix). The co-IP buffer using NP-40 has been previously used to ex-
amine interactions of p75NTR with other intracellular proteins, such as TRAF-6 
(Khursigara et al., 1999) and PKA (Higuchi et al., 2003). For mapping 
 experiments, PDE4A5 cDNA was cotransfected with HA-tagged p75NTR 
deletion constructs into HEK293 cells. IP was performed with an anti-HA 
antibody (Cell Signaling). Cell lysates were probed with an anti-PDE4A or 
an anti-p75NTR antibody (9651). For co-IP experiments using recombinant 
proteins, equimolar amounts (2 μM) of purifi ed recombinant MBP-PDE4A5 
(O’Connell et al., 1996), MPB-PDE4A4 (McPhee et al., 1999), MBP-
PDE4D3 (Yarwood et al., 1999), and GST-p75NTR-ICD (Khursigara et al., 
2001) were mixed in binding buffer (50 mM Tris-HCl, pH 7.5, 100 mM 
NaCl, 2 mM MgCl2, 1 mM DTT, 0.5% Triton X-100, and 0.5% BSA) and 
incubated for 1 h at 4°C. Washed glutathione-Sepharose beads were 
added according to the manufacturer’s instructions for an additional hour. 
Beads were sedimented by centrifugation (10,000 g for 1 min) and washed 
three times. Proteins associated with the beads were eluted by boiling in 
loading buffer and separated by SDS-PAGE.
RT-PCR and real-time PCR
RT-PCR was performed as described previously (Akassoglou et al., 2002). 
Primers for tPA, uPA, and PAI-1 genes were used as described previously 
(Yamamoto and Loskutoff, 1996). Real-time PCR was performed using 
the Opticon DNA Engine 2 (MJ Research) and the Quantitect SYBR 
Green PCR kit (QIAGEN). Results were analyzed with Opticon 2 soft-
ware using the comparative Ct method as described previously (Livak and 
Schmittgen, 2001). Data were expressed as ∆∆Ct for the tPA gene nor-
malized against GAPDH.
Quantifi cation of tPA and uPA activity
Quantifi cation of tPA and uPA activity in SC and fi broblast in lysates and 
supernatants was performed according to the directions of the activity as-
say kits from American Diagnostica and Chemicon, respectively. To elevate 
cAMP cells were treated either with 2 mM db-cAMP (Sigma-Aldrich) or with 
10 μM forskolin (Sigma-Aldrich) for 16 h. To block PKA activity, cells were 
treated with 200 nM KT5720 (Calbiochem). Induction with neurotrophins 
was performed using 100 ng/ml NGF and 50 ng/ml BDNF for 16 h before 
tPA assay.
Fibrin degradation assay
Coating with fi brin was prepared as described previously (Lansink et al., 
1998). To quantitate fi brin degradation, the supernatant was aspirated 
and the remaining gel was weighed using an analytical balance. Decrease 
of gel weight corresponded to increased fi brin gel degradation.
Cell culture and transfections
Murine SCs were isolated as described previously (Syroid et al., 2000). 
NIH3T3 or HEK293 cells were cotransfected either with p75NTR FL, ICD 
or deletion constructs, and PDE4A5 cDNAs using Lipofectamine 2000 
(Invitrogen) as described in the Results section. CGNs were isolated 
from P10 animals (Yamashita and Tohyama, 2003). CGNs were lysed 
immediately for co-IP, without plating. siRNA directed against p75NTR 
(Dharmacon) was transfected into SCs and NIH3T3p75NTR cells using 
Dharmafect (Dharmacon).
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cAMP/PKA assays
106 fi broblasts or 500,000 SCs were lysed in 0.1 N HCl solution and cAMP 
was measured using a competitive binding cAMP ELISA (Assay Designs). 
Cells were treated with 100 ng/ml PTX for 16 h. For inhibition of PDE activity, 
cells were treated for 16 h with 500 μM isobutyl methylxanthine (IBMX; 
Calbiochem), 18.7 μM 8-methoxymethyl-3-isobutyl-1-methylxanthine (PDE1 
inhibitor; Calbiochem), 80 μM erythro-9-(2-Hydroxy-3-nonyl)adenine (PDE2 
inhibitor; Calbiochem), 100 nM trequinsin (PDE3 inhibitor; Calbiochem), 
and 10 μM rolipram (PDE4 inhibitor; Calbiochem). Cells were treated with 
forskolin in the presence of the inhibitors for 1 h. Because these inhibitors 
specifi cally inhibit a PDE isoform and have no effect on the other PDE iso-
enzymes (Beavo and Reifsnyder, 1990), they are extensively used for the 
identifi cation of the specifi c PDE isoform that is involved in different cellular 
functions. Induction with neurotrophins was performed using 100 ng/ml 
NGF or 50 ng/ml BDNF, 750 ng/ml of FcTrkB, or 1.35 ug/ml of Fcp75NTR 
for 1 h before cAMP assay. For the qualitative and quantitative PKA assay 
(Promega), cells were treated with 10 μM forskolin for 30 min, lysed in 1% 
NP-40 buffer with 150 mM NaCl, 50 mM Tris, and 1 mM EGTA, and pro-
tein concentration was determined using the Bradford Assay (Bio- Rad Labo-
ratories). 1 μg was loaded into the PKA assay reaction mix according to the 
manufacturer’s protocol (Promega).
In situ zymography
In situ zymographies were performed as described previously (Akassoglou 
et al., 2000). Quantifi cation of in situ zymographies was performed by 
measuring the area of the lytic zone surrounding each nerve, and dividing 
that value by the area of the nerve. Images were collected after 8 h of incu-
bation for the sciatic nerve and 4 h of incubation for the lung. For cell 
zymographies, cultures were washed four times with PBS/BSA and overlaid 
with 200 μl of Dulbecco’s minimum essential medium containing 1% LMP 
agarose, 2.5% boiled nonfat milk, and 25 μg/ml human plasminogen. 
The overlay was allowed to harden, and plates were incubated in a cell 
culture incubator at 37°C. Pictures of lytic zones were taken using an 
 inverted microscope under dark fi eld (Carl Zeiss MicroImaging, Inc.).
Construction of pm-AKAR2.2 and PDE4A4𝛅CT
For the construction of pm-AKAR2.2 we used the previously described cyto-
plasmic PKA sensor, AKAR2 (Zhang et al., 2005). pm-AKAR2.2 consists of 
a cDNA containing a FRET pair, monomeric enhanced cyan fl uorescent pro-
tein (ECFP), and monomeric citrine (an optimized version of YFP), fused to 
forkhead associated domain 1 (FHA1) (Rad53p 22–162), and the PKA sub-
strate sequence LRRATLVD via linkers. A206K mutations were incorporated 
to ECFP and Citrine by the QuikChange method (Stratagene). The C-terminal 
sequence from K-Ras K K K K K K S K T K C V I M was added to target the construct 
to the plasma membrane. For expression in mammalian cells, the chimaeric 
proteins were subcloned into a modifi ed pcDNA3 vector (Invitrogen) behind 
a Kozak sequence as described previously (Zhang et al., 2005).
For the generation of the PDE4A4δCT, PDE4A4 was subcloned into 
p3XFLAG-CMV-14 using plasmid pde46 (GenBank/EMBL/DDBJ acces-
sion no. L20965) as template from Met-1 to Iso-721 (McPhee et al., 1999). 
A forward (5′) primer containing a HindIII restriction site immediately 5′ to 
the initiating Met-1 (ATG) of PDE4A4 and a reverse primer designed to the 
DNA sequence ending at Iso-721 (ATA) with BamHI restriction site immedi-
ately 3′ to Iso-721 was used to amplify Met-1 to Iso-721. The C terminus 
was removed simply by amplifying from Iso-721 instead of the fi nal codon 
at the end of the full-length PDE4A4B. The C-terminally truncated PDE4A4B 
was cloned in-frame with three FLAG (Asp-Tyr-Lys-Xaa-Xaa-Asp) epitopes 
(Asp-726, Asp-733 & Asp-740) after the BamHI restriction site, therefore at 
the C terminus of the now-truncated PDE4A4. The stop codon (TAG) after 
the FLAG epitopes is located immediately after Lys-747. This strategy gen-
erates a C-terminal truncate of PDE4A4 from 1–721.
FRET imaging
NIH3T3 cells and NIH3T3p75NTR cells were transiently transfected with 
pm-AKAR2.2, AKAR3, or pm-AKAR3 (Allen and Zhang, 2006) and im-
aged within 24 h of transfection. Cells were rinsed once with HBSS (Cellgro) 
before imaging in HBSS in the dark at room temperature. An Axiovert 
microscope (Carl Zeiss Microimaging, Inc.) with a MicroMax digital camera 
(Roper-Princeton Instruments) and MetaFluor software (Universal Imaging 
Corp.) was used to acquire all images. Optical fi lters were obtained from 
Chroma Technologies. CFP and FRET images were taken at 15-s intervals. 
Dual emission ratio imaging used a 420/20-nm excitation fi lter, a 450-nm 
dichroic mirror and a 475/40-nm or 535/25-nm emission fi lter for CFP 
and FRET, respectively. Excitation and emission fi lters were switched in fi lter 
wheels (Lambda 10–2; Sutter Instrument Co.).
Peptide array mapping
Peptide libraries were synthesized by automatic SPOT synthesis (Frank, 
2002). Synthetic overlapping peptides (25 amino acids in length) were 
spotted on Whatman 50 cellulose membranes according to standard pro-
tocols by using Fmoc-chemistry with the AutoSpot Robot ASS 222 (Intavis 
Bioanalytical Instruments AG). Membranes were overlaid with 10 μg/ml 
recombinant GST-p75NTR ICD. Bound recombinant GST-p75NTR ICD (Khursi-
gara et al., 2001) was detected using rabbit anti-GST (1:2,000; GE 
Healthcare) followed by secondary anti–rabbit horseradish peroxidase 
 antibody (1:2,500; Dianova). Alanine scanning was performed as described 
previously (Bolger et al., 2006).
Statistics
Statistical signifi cance was calculated using JMP2 Software by unpaired 
t test for isolated pairs or by analysis of variance (one-way ANOVA) for mul-
tiple comparisons. Data are shown as the mean ± SEM.
Online supplemental material
Fig. S1 shows that genetic loss of p75NTR increases tPA mRNA levels and 
proteolytic activity in the cerebellum. Fig. S2 demonstrates that treatment 
with neurotrophins has no effect on cAMP levels in NIH3T3 cells. Fig. S3 
shows endogenous coimmunoprecipitations of PDE4A5 and p75NTR from 
injured sciatic nerve and from primary CGNs. Fig. S4 shows results from 
transient transfections of NIH3T3 cells with p75NTR and the PKA activity 
reporters, AKAR3 and pm-AKAR3. Fig. S5 shows that inhibition of PDE4s 
with rolipram decreases fi brin deposition both in LPS-induced lung fi brosis 
and sciatic nerve crush injury. The online version of this article is available 
at http://www.jcb.org/cgi/content/full/jcb.200701040/DC1.
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